Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY24 results · Jan–Mar 2024
Suven Life Sciences reported revenue from operations of ₹2.39 crore (down 8.7% from Q4 FY23) and net loss of ₹26.54 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.39 | 2.61 | −8.7% | 2.45 | −2.7% |
| Other income | 4.28 | 5.60 | −23.5% | 6.07 | −29.4% |
| Total income | 6.67 | 8.21 | −18.8% | 8.52 | −21.7% |
| Profit before tax | (27.54) | (27.64) | Loss narrowed | (41.76) | Loss narrowed |
| Net profit for the period | (26.54) | (27.64) | Loss narrowed | (41.76) | Loss narrowed |
| EPS, basic (₹) | (1.22) | (1.17) | Loss widened | (1.92) | Loss narrowed |
| Net margin (%) | -1112.7 | -1058.7 | -1704.1 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.39 | 2.61 | −8.7% | 2.45 | −2.7% |
| Other income | 4.28 | 5.60 | −23.5% | 6.07 | −29.4% |
| Total income | 6.67 | 8.21 | −18.8% | 8.52 | −21.7% |
| Profit before tax | (4.13) | (2.25) | Loss widened | (4.77) | Loss narrowed |
| Net profit for the period | (3.12) | (2.25) | Loss widened | (4.77) | Loss narrowed |
| EPS, basic (₹) | (0.14) | (0.05) | Loss widened | (0.22) | Loss narrowed |
| Net margin (%) | -131.0 | -86.1 | -194.6 |
Consolidated
- Filed with BSE
- 09 May 2024, 15:36 IST
- Board meeting
- 06 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 May 2024, 15:36 IST
- Board meeting
- 06 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE